Zydus Lifesciences Ltd.
NSE: ZYDUSLIFE · Pharmaceuticals
Snapshot
Unlock Zydus Lifesciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zydus Lifesciences Limited is a global pharmaceutical company engaged in the research, development, and manufacturing of finished dosage human formulations, active pharmaceutical ingredients, and consumer wellness products. The company operates across diverse therapeutic areas including oncology, neurology, and dermatology, while maintaining a significant presence in both domestic and international markets.
Business Model
The company generates revenue through the sale of generic and specialty pharmaceutical formulations, biosimilars, vaccines, and a portfolio of consumer wellness brands. It leverages an integrated business model that spans from research and development to global distribution and retail pharmacy operations.
Growth Outlook
Growth is driven by a robust pipeline of biological products and specialty formulations targeting complex therapeutic areas. The company continues to expand its global footprint and invest in research to strengthen its position in the generics and biosimilars markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical market and government-mandated price controls in various jurisdictions may impact profit margins.
- R&D Execution. The long-term growth strategy relies on the successful development and commercialisation of complex biological products and specialty drugs, which carry inherent clinical and regulatory risks.
- Currency Volatility. As a global entity with significant operations in the US and other international markets, the company is exposed to fluctuations in foreign exchange rates.
Start your research today
Unlock AI insights, financials, peers and live data on Zydus Lifesciences Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹28,592 Cr
TTM · consolidated
NET PROFIT
₹4,593 Cr
TTM · consolidated
EPS
₹44.87
TTM · consolidated
RETURN ON EQUITY
18.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.1%
TTM · consolidated
P/E
25.5×
Q1 FY27 · consolidated
EV/EBITDA
14.7x
Q1 FY27 · consolidated
EBITDA MARGIN
30.7%
TTM · consolidated
NET PROFIT MARGIN
12.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.18L Cr | 25.5× | 14.66 | 21.1% | 30.7% | 18.0% | 20.1% | +15.6% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 32.2× | 18.10 | 1.8% | 21.6% | 10.2% | 13.6% | -11.2% |
Laurus Labs Ltd.LAURUSLABS | ₹1.10L Cr | 97.9× | 53.70 | 22.6% | 28.7% | 22.3% | 25.3% | +127.5% |
Mankind Pharma Ltd.MANKIND | ₹1.02L Cr | 51.2× | 25.95 | 14.4% | 28.2% | 13.5% | 14.3% | +3.9% |
Dr. Reddy's Laboratories Ltd.DRREDDY | ₹1.01L Cr | 31.2× | 16.13 | -0.9% | 19.8% | 8.9% | 11.4% | -3.1% |
Aurobindo Pharma Ltd.AUROPHARMA | ₹99,051 Cr | 26.2× | 12.80 | 9.1% | 22.3% | 10.5% | 15.4% | +54.4% |
As of Q1 FY27
Financials
Zydus Lifesciences Ltd.
NSE: ZYDUSLIFE · Pharmaceuticals
Snapshot
Unlock Zydus Lifesciences Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zydus Lifesciences Limited is a global pharmaceutical company engaged in the research, development, and manufacturing of finished dosage human formulations, active pharmaceutical ingredients, and consumer wellness products. The company operates across diverse therapeutic areas including oncology, neurology, and dermatology, while maintaining a significant presence in both domestic and international markets.
Business Model
The company generates revenue through the sale of generic and specialty pharmaceutical formulations, biosimilars, vaccines, and a portfolio of consumer wellness brands. It leverages an integrated business model that spans from research and development to global distribution and retail pharmacy operations.
Growth Outlook
Growth is driven by a robust pipeline of biological products and specialty formulations targeting complex therapeutic areas. The company continues to expand its global footprint and invest in research to strengthen its position in the generics and biosimilars markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical market and government-mandated price controls in various jurisdictions may impact profit margins.
- R&D Execution. The long-term growth strategy relies on the successful development and commercialisation of complex biological products and specialty drugs, which carry inherent clinical and regulatory risks.
- Currency Volatility. As a global entity with significant operations in the US and other international markets, the company is exposed to fluctuations in foreign exchange rates.
Start your research today
Unlock AI insights, financials, peers and live data on Zydus Lifesciences Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹28,592 Cr
TTM · consolidated
NET PROFIT
₹4,593 Cr
TTM · consolidated
EPS
₹44.87
TTM · consolidated
RETURN ON EQUITY
18.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.1%
TTM · consolidated
P/E
25.5x
Q1 FY27 · consolidated
EV/EBITDA
14.7x
Q1 FY27 · consolidated
EBITDA MARGIN
30.7%
TTM · consolidated
NET PROFIT MARGIN
12.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27